Cytokinetics (NASDAQ:CYTK) Stock Price Expected to Rise, Leerink Partners Analyst Says

Cytokinetics (NASDAQ:CYTK) had its price objective increased by research analysts at Leerink Partners from $83.00 to $84.00 in a research note issued on Thursday,Benzinga reports. The brokerage presently has an “outperform” rating on the biopharmaceutical company’s stock. Leerink Partners’ target price would suggest a potential upside of 35.00% from the company’s current price.

A number of other research firms have also recently issued reports on CYTK. Citizens Jmp upped their price target on shares of Cytokinetics from $88.00 to $96.00 and gave the company a “market outperform” rating in a report on Wednesday. Needham & Company LLC increased their target price on Cytokinetics from $84.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. lifted their price target on Cytokinetics from $70.00 to $74.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, January 21st. Finally, Barclays started coverage on Cytokinetics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $87.00 price objective for the company. Seventeen equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $88.83.

Cytokinetics Stock Down 0.7%

Shares of Cytokinetics stock opened at $62.22 on Thursday. Cytokinetics has a 12-month low of $29.31 and a 12-month high of $70.98. The stock has a 50 day moving average price of $64.20 and a two-hundred day moving average price of $58.58. The stock has a market capitalization of $7.61 billion, a P/E ratio of -9.53 and a beta of 0.54.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Tuesday, February 24th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million for the quarter, compared to analyst estimates of $8.02 million. The company’s revenue was up 4.9% compared to the same quarter last year. During the same period last year, the firm earned ($1.26) EPS. Sell-side analysts anticipate that Cytokinetics will post -5.24 earnings per share for the current year.

Insider Transactions at Cytokinetics

In other news, EVP Andrew Callos sold 52,486 shares of the stock in a transaction on Friday, December 5th. The shares were sold at an average price of $65.95, for a total value of $3,461,451.70. Following the completion of the transaction, the executive vice president owned 50,660 shares in the company, valued at approximately $3,341,027. This represents a 50.89% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $61.24, for a total transaction of $134,728.00. Following the sale, the executive vice president owned 138,552 shares in the company, valued at approximately $8,484,924.48. This trade represents a 1.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 151,385 shares of company stock valued at $9,817,158 over the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Cytokinetics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after purchasing an additional 191,336 shares in the last quarter. State Street Corp raised its holdings in shares of Cytokinetics by 3.7% in the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock worth $370,139,000 after buying an additional 207,961 shares in the last quarter. Deep Track Capital LP lifted its position in shares of Cytokinetics by 17.8% during the 3rd quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after buying an additional 650,000 shares during the period. Geode Capital Management LLC lifted its position in shares of Cytokinetics by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after buying an additional 15,815 shares during the period. Finally, Vestal Point Capital LP boosted its stake in Cytokinetics by 14.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after buying an additional 384,469 shares in the last quarter.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Leerink Partners raised its price target from $83 to $84 and kept an “outperform” rating, signaling continued institutional confidence in the stock’s upside potential. Leerink Partners raise
• Positive Sentiment: HC Wainwright continues to rate CYTK a “Buy” with a $136 price target — an aggressive upside relative to current levels, which supports longer-term investor optimism despite near-term volatility. HC Wainwright coverage
• Positive Sentiment: Investor commentary pieces remain bullish (e.g., recent “Why Cytokinetics is a Buy” article), which can help sustain retail interest and buying momentum over time. Why CYTK is a buy
• Neutral Sentiment: Reported short-interest data for late February shows anomalous/zero values (0 shares, 0.0 days-to-cover) — likely a data/reporting issue, so it provides no clear signal about directional pressure.
• Negative Sentiment: Shares moved down after the company’s recent quarterly report missed EPS expectations and triggered a negative market reaction; coverage noted a sharp intraday decline following the results. Weak earnings coverage
• Negative Sentiment: HC Wainwright cut EPS forecasts across FY2026–FY2028 and several quarters (Q1–Q4 2026), materially lowering near‑term profitability expectations even as it held a buy rating — a factor pressuring valuation multiples today. HC Wainwright estimate changes

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.